A recombinant partial protein sequence (within amino acids 1-95) from the human protein was used as the immunogen for the MIG9 antibody.
S100P is a 95-amino-acid protein and a member of the S100 family. S100P has been shown to mediate tumor growth, metastasis and invasion through the binding of Ca2+ ions, receptor for advanced glycation end products, cytoskeletal protein ezrin, calcyclin-binding protein/Siah-1-interacting protein and cathepsin D. S100P highly expressed in human placenta, gastrointestinal tract, and esophageal mucosa, but always negative in pancreas and liver. Overexpression of S100P has been detected in several cancers such as breast, colon, prostate, pancreatic and lung carcinomas, and the protein has been functionally implicated in carcinogenic processes. S100P could potentially serve as diagnostic marker, prognostic/predictive indicator and therapy target for different carcinomas.
